

August 05, 2022

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**Subject: Outcome of the Board Meeting held on August 05, 2022, Friday, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.**

**SYMBOL: AJOONI**

Dear Sir/Madam,

With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held on Friday, August 05, 2022 at 11.00 a.m concluded at 11.30 a.m. Following transactions were considered and approved:

1. Un-Audited Financial Results for the quarter ended on 30th June 2022
2. Limited Review Report from the auditor for the quarter ended 30th June 2022.

You are requested to kindly take the same on your record and acknowledge receipt.

Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited

  
Jasjot Singh  
Managing Director  
DIN: 01937631



August 05, 2022

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**SYMBOL: AJOONI**

**Sub.: Approval of Un-audited Financial Results for the quarter ended 30<sup>th</sup> June, 2022.**

Dear Sir,


Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 05/08/2022 at the Registered Office of the company have considered and approved the Un-audited Financial Results for the quarter ended 30<sup>th</sup> June, 2022. In this regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter ended on 30th June 2022
2. Limited Review Report from the auditor for the quarter ended 30th June 2022.

You are requested to kindly take the same on record.

Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited

Jasjot Singh  
Managing Director  
DIN: 01937631






**AJOONI BIOTECH LIMITED**

**CIN : L85190PB2010PLC040162**

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022 (In Lakhs)**

PARTICULARS	Quarter Ended				Year Ended (Audited)
	30.06.2022	31.03.2022	30.06.2021	Period Ended (UnAudited)	
			30.06.2022	30.06.2021	
<b>I Income</b>					
Revenue from operations	1,231.07	2,051.19	1,584.62	1,584.62	7403.77
Other income	0.78	1.42	0.92	0.92	3.81
<b>Total income from operations</b>	<b>1,231.85</b>	<b>2,052.61</b>	<b>1,585.54</b>	<b>1,585.54</b>	<b>7,407.58</b>
<b>II Expenses</b>					
Cost of Material Consumed	1,072.05	1,765.04	1,342.82	1,342.82	6,391.49
Change In Inventories	(42.22)	7.05	(1.49)	(1.49)	9.84
Employee benefit expenses	52.45	23.16	38.10	52.45	148.14
Finance costs	9.92	10.63	13.30	9.92	54.00
Depreciation and amortization expenses	24.94	28.89	18.93	24.94	111.07
Payment to NSE					
Other expenses	72.62	213.18	133.08	72.62	546.93
<b>Total expenses</b>	<b>1,189.76</b>	<b>2,047.95</b>	<b>1,544.74</b>	<b>1,189.76</b>	<b>7,261.47</b>
<b>Profit/(Loss) before exceptional items and tax</b>	<b>42.09</b>	<b>4.66</b>	<b>40.80</b>	<b>42.09</b>	<b>146.11</b>
<b>IV Exceptional items</b>					
<b>V Profit/(Loss) before tax</b>	<b>42.09</b>	<b>4.66</b>	<b>40.80</b>	<b>42.09</b>	<b>146.11</b>
<b>VI Tax expenses</b>					
a) Current tax	10.94	9.72	10.50	10.94	44.76
b) Deferred tax	1.05	-1.07	1.05	1.05	3.53
b) Mat Credit	-	-	-	-	-
<b>VII Net Profit/(Loss) for the period/year</b>	<b>32.20</b>	<b>(6.13)</b>	<b>31.35</b>	<b>32.20</b>	<b>104.88</b>
<b>VIII Other comprehensive income (net of tax)</b>					
Items that will not be reclassified to profit or loss:	-	(37)	-	-	(32)
<b>Total other comprehensive income</b>					
<b>IX Total comprehensive income for the period/year (VII+VIII)</b>	<b>32.20</b>	<b>(42.78)</b>	<b>31.35</b>	<b>32.20</b>	<b>73.16</b>
<b>X Paid-up equity share capital (face value of the share shall be indicated)</b>	<b>1,000.55</b>	<b>1,000.55</b>	<b>1,000.55</b>	<b>1,000.55</b>	<b>1,000.55</b>
<b>XI Other equity (excluding revaluation reserve)</b>	<b>656.61</b>	<b>637.97</b>	<b>596.69</b>	<b>656.61</b>	<b>637.67</b>
<b>XII EPS in Rs. (Face Value of Rs.10/- each)*</b>					
-Basic	0.32	(0.06)	0.31	0.31	1.05
-Diluted	0.32	(0.06)	0.31	0.31	1.05



T. Tor


**Notes:**

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 05.08.2022 after being reviewed by the Audit Committee.
2. The company is having single segment in accordance with IND AS 108 "operating segments" and there/ore segment reporting is not applicable to the Company.
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

**Date:** 05/08/2022

**Place :** Mohali

For Ajooni Biotech Limited  
  
Jasjot Singh  
Managing Director  
DIN:  
01937631




**AJOONI BIOTECH LIMITED****CIN : L85190PB2010PLC040162**

Statement of Assets and Liabilities

For the Quarter ended on 30th June 2022

in Rs.

	PARTICULARS	30TH JUNE 2022	31ST MARCH 2022
<b>I. ASSETS</b>			
<b>(1)</b>	<b>Non - Current Assets</b>		
	a) Property, Plant and Equipment	59,633,145	62,052,358
	b) Financial Assets		
	(1) Non-Current Investments	7,040,905	7,038,909
	(2) Advances	0	0
	c) Deffered Tax Asset	1,923,383	1,818,383
	d) Other Non Current Assets	0	0
<b>(2)</b>	<b>Current Assets</b>		
	a) Inventories	68,636,127	58,817,040
	b) Financial Assets		
	(1) Cash & Cash Equivalent	1,647,790	573,855
	(2) Short Term Loans and advances	15,876,928	21,471,815
	(3) Trade Receivables	105,272,757	138,402,877
	c) Other Current Asset	0	0
	<b>TOTAL (RS.)</b>	<b>260,031,035</b>	<b>290,175,237</b>
<b>II EQUITY AND LIABILITIES</b>			
<b>(1)</b>	<b>Equity</b>		
	a) Equity Share Capital	100,055,820	100,055,820
	b) Other Equity	66,989,532	63,767,836
<b>(2)</b>	<b>Non-Current Liabilities</b>		
	a) Financial Liabilities		
	(1) Borrowings	18,587,239	25,763,844
<b>(3)</b>	<b>Current Liabilities</b>		
	a) Financial Liabilities		





(1) Borrowings	43,335,735	27,740,793
(2) Trade Payables	22,833,420	67,991,141
b) Other Current Liabilities	2,659,029	379,543
c) Current tax liabilities (Net)	5,570,260	4,476,260
<b>TOTAL (RS.)</b>	<b>260,031,036</b>	<b>290,175,237</b>

Date: 05/08/2022

Place: Mohali

For Ajooni Biotech Limited

T To

Jasjot Singh

Managing Director

DIN: 01937631





# Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

## Limited Review Report on Standalone Financial Results

### To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. **Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 30<sup>th</sup> JUNE 2022 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co,  
Chartered Accountants  
Konica Madan

CA Konica Madan  
Partner

M.No 547759

Date : 05.08.2022

UDIN : 22547759AOIAJQ2190

House No. 1122, Sector 71, Mohali

Mobile : 096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com